Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial services are designed to seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA Future […]
US Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP™ exosome purification technology. LEAP™ enables large-scale, clinical grade commercial production of exosomes needed to underpin the emerging field of exosome medicines. Exopharm is seeking potential partners and licensees, with LEAP™ having the potential to become the industry standard for exosome […]
Stockhead Article Exopharm has focused on R&D along with key appointments during the start of the new financial year to support its ambitious goal of becoming a leading global exosome medicine company. Shares in exosome medicine company Exopharm (ASX: EX1) peaked almost 12% today after a positive Q1FY22 trading update, with the company making significant advances in […]
Mr David Oxley appointed as President – International Dr Johannes K Mühl appointed as Senior Vice President – Finance 4 October 2021, Melbourne, Australia: Exosome medicines company, Exopharm Limited (ASX: EX1) has made two senior appointments in support of its international strategy. Mr David Oxley appointed as President – International David Oxley’s appointment extends the company’s reach […]
Exopharm is a step closer to being granted a US patent for the LEAP technology. The USPTO has issued a ‘Notice of Allowance Mailed’ note for the LEAP patent application (Application 17/147,033). At this point, a USPTO patent number has not been issued in relation to the Application and there are some formalities that need […]
Our peer-reviewed LEAP paper published in BioProcess International is one of 4 nominees for the 2021 BPI Readers’ Choice Awards and is amongst the top 4 popular articles for downstream processing. The paper validates the Ligand-based Exosome Affinity Purification (LEAP) technology as a proprietary answer to the downstream processing bottleneck of exosome purification. Click here to have […]
Exopharm signs deal with Japanese chemical company as LEAP tech promise to accelerate new cancer-beating research
STOCKHEAD ARTICLE Exopharm will conduct a research collaboration with Japan’s Showa Denko Materials as its LEAP technology shows promise at reducing a major obstacle in the advancement of exosomes as a new form of regenerative medicine for diseases such as cancer. Melbourne Biotech company Exopharm (ASX:EX1) has announced it will undertake a research collaboration with Japan’s Showa […]
On August 26 we presented our Science Webinar with Dr Jennifer King and Dr Anna Cifuentes-Rius about overcoming the delivery challenge for nucleic acid drugs. Deputy CEO & Chief Commercial Officer, Dr Chris Baldwin hosted the event and there was Q&A at the end of the presentations. After the technical and scientific questions were answered, […]
We are excited to announce the publishing of our review article titled From mesenchymal stromal cells to engineered extracellular vesicles: A new therapeutic paradigm. You can access the paper on the Frontiers in Cell and Developmental Biology journal here. Abstract Mesenchymal stromal cells (MSCs) are multipotent cells obtained from many tissues including bone marrow, adipose […]
Here is the recording from Exopharm’s shareholder update webinar held on 13 July 2021. Founder & CEO, Dr Ian Dixon, provided an update on RNA delivery using exosomes and developments relating to Exopharm’s LEAP technology IP. Following this, CCO/Deputy CEO, Dr Chris Baldwin discussed ongoing commercial activity relating to the Company. The webinar was hosted […]
Here is our latest investor presentation from Stockhead’s V-Con. This video conference focuses on the Australian biotech sector, medical innovations and breakthrough treatments. Deputy CEO & Chief Commercial Officer, Dr Chris Baldwin provides updates on the exosome technology and exosome medicines programs at Exopharm.
We are pleased to announce that our first LEAP Paper has been published. In our studies, ligand-based exosome affinity purification (LEAP) technology has proven to be an efficient, robust, scalable, low-cost, and highly reproducible EV purification platform technology. The patented technology is suited to the manufacture of naive EV and engineered EV products. When compared […]
Our next video in our ‘Life of Science’ series stars Chantelle Blyth – our Research Scientist from the Upstream Processing Team. One of the key aspects of Chantelle’s role is upscaling our cell culture process from millilitres to litres. Inquisitive and vibrant, she tackles challenges with a creative edge to get tangible end results. Chantelle is passionate […]
Investment research, investor relations and consulting firm Edison Group initiates research on Exopharm.
“The proceeds from the capital raise together with the 2021 R&D rebate later in the year will put the company in a strong financial position to realise its strategy of becoming a world leader in exosome medicines through the commercialisation of its technology platforms and the development of new exosome medicine,” says Chief Executive Officer […]
“With its foundation LEAP technology, Exopharm has arguably the world’s best tools for manufacturing exosomes,” Pitt Street analysts Stuart Roberts and Cheng Ge wrote. We are proud to be at the forefront of the emerging exosome medicines field and for the many opportunities ahead. Click here for the full Stockhead article.
Pitt Street Research has published a 29-page report on Exopharm. Base case valuation of $2.80 per share ($0.66 today), driven by the company’s LEAP technology. Access the full Pitt Street Report here. To go to the Pitt Street Research page, click here.
Watch Dr Chris Baldwin, Deputy CEO & COO, as he explains Exopharm’s latest developments and potential target markets. 0:00 – Intro 0:10 – What is your business about? 1:20 – Tell us about your product developments and pipeline? 3:01 – What is the size of your potential target markets? 4:16 – What is EX1’s competitive advantage? 5:30 – How did your […]
“Dr Laitinen and her team are the perfect first partners for manufacturing Plexaris and other blood EV products for Europe. We are equally excited to be preparing to transfer the LEAP technology to FRCBS so they can produce blood cell derived EV medicines,” said Dr Chris Baldwin, Chief Commercial Officer. “For Exopharm, this is the first […]
In this webinar, Dr Ian Dixon, Exopharm’s Managing Director and Founder, discusses three recent ASX announcements and answers questions in a Q&A facilitated by Paul Hart, Executive Director of Canary Capital. The following ASX announcements are addressed: 01/04/2021 Preclinical Data from Osteoarthritis Animal Study 06/04/2021 Positive PLEXOVAL II Phase 1 Clinical Trial Results 06/04/2021 LEAP Technology- Advanced EV […]
We presented at the Twilight Investor Briefing on March 11 hosted by FB Rice and organised by Monsoon Communications. We would like to thank the organisers for the opportunity to share our exosome medicine strategy, unique technology platform and show why this is the Year We LEAP as we work to empower exosome medicine discovery […]
“I was more driven last year than ever before to really find that anti-viral to get it into the clinic”, said Dr. Ranja Salvamoser, Head of Experimental Biology. In light of International Women’s Day today, and every other day, we celebrate the work and achievements of the incredible women in our company. Ranja is leading her […]
With International Women’s Day around the corner, we share with you our third profile video featuring Aislinn Treloar, our multi-talented Business Development Manager. As an inspiring and humble leader, Aislinn has played a pivotal role in advancing our technologies through collaborations and partnerships and is one of the many amazing women who work at Exopharm.
“People have begun to understand that our destiny is not only in our hands, it is in the hands of the entire exosome research community, and everybody who is trying to develop exosome medicines, because there’s no technology that has been demonstrated that can produce thousands, much less tens of thousands or hundreds of thousands […]
Early Careers in Science Webinar – Hosted by Exopharm 18 February 2021 12-12.45pm AEDT Choosing a career path can be daunting, and we understand this. Aimed at high school students, this free webinar provided some insight into a career in science and featured speakers from Exopharm who are passionate about helping students embrace this field. […]
We presented at the BIO CEO & Investor Digital Conference which is taking place from 16-18 February. Our Chief Commercial Officer, Dr. Chris Baldwin, provided insight into our company, exosomes in general and the technologies we are using to bring exosome therapeutics to the world. You can find the slide deck here.
Today we share with you the second profile video in our series called “The Life of Science”. This video features Sam Law, our Process Engineer. Sam drives the execution of all things related to exosome isolation and manufacturing. He is a true team player and a tinkerer by nature.
Watch our interview at the Edison Group Open House: Global Healthcare 2021 Conference.
Producing EVs at the Clinical Scale On November 11, we presented at the Exosome Based Therapeutic Development Digital Summit. At this key exosome industry event, we had the opportunity to highlight our LEAP technology, the team’s accomplishments and our commitment to collaboration to advance the development of all exosome therapeutics. Our Chief Commercial Officer, Dr […]
“The biggest problem is to purify the EVs from their source and to eliminate the contaminants, and not damage the EVs,” says Managing Director and founder Dr Ian Dixon. One of the great things about our LEAP technology and process is that it is scalable. You can read the full Stockhead article here.
Chief Commercial Officer, Dr Chris Baldwin, will present to the Exosome Based Therapeutic Development Digital Summit on 11 November (9:00 AM US Eastern Time, 1.00 AM AEDT), the first day of the two-day event. You can find the slide deck here.
Our science is too important to leave to just the scientists. On November 5, Dr Balarka Banerjee and Dr Kartini Asari explained some of the advances Exopharm is making. This science update forms part of our ‘Behind the Scenes’ webinar series. Stem Cells: Exosome Factories Dr. Balarka Banerjee, Cell Development Manager Exopharm’s unique LEAP […]
“With a successful outcome from PLEXOVAL II, Exopharm will be well-positioned to initiate Phase 2 studies with off-the-shelf Plexaris and Phase 1 studies with our mesenchymal stem cell EV product Cevaris,” said Angus Tester, Head of Product Evaluation. You can read the full Stockhead article here.
Yesterday, Chief Commercial Officer Chris Baldwin sat down with Stockhead’s resident health and biotech expert Tim Boreham for the latest episode of The Health Kick Podcast. They discuss the potential of exosomes to transform healthcare, and our journey to commercialising our exosome therapeutics. Click below to listen. You can find the full post here.
How mRNA vaccines could defeat the novel coronavirus Head of Innovation Andy Coley spoke with Stockhead about the potential of mRNA for fighting COVID-19, including Moderna’s vaccine candidate and Fortrexo, our engineered EV approach. You can find the full article here.
ShareCafe’s “Hidden Gems” Webinar 18 Sept 2020 Chief Commercial Officer Chris Baldwin provides updates on Exopharm’s Technology and Naive EV programs, including the addition of Alison Mew to the senior leadership and the progress on Exopharm’s second clinical trial.
Behind the Scenes with our Scientists Recently, there has been a variety of updates about the company’s business progress and accomplishments. This webinar provided a closer look at some of science and technology behind our most recent advances, Fortrexo CoV™ and Exoria™. RNAi’s to Stop Coronavirus Dr Karen Holden, Head of Translation Exopharm has […]
Exopharm has announced a placement of shares to raise $10 million. Canary Capital, the manager of the placement, and its directors have elected to take the majority of their fees in shares. “In Exopharm, Canary has identified an Australian company with proprietary technology that can compete on the world stage”, says Paul Hart, Executive Director […]
“As a serial biotechnology entrepreneur, Dr Dixon doesn’t just develop technologies or products – he wants to build long-lasting businesses based upon big ideas.” Written by our Chief Commercial Officer Chris Baldwin, this Sharecafe article explains Dr Dixon’s big idea back in 2013 and how it led to the foundation of Exopharm. Today, Exopharm is […]
Exopharm CCO Dr Chris Baldwin gives a shareholder update on the ‘Morning Twilight Briefing’ webinar series hosted by Monsoon Communications. Chris discusses Exopharm’s key development areas and provides an overview of the company’s engineered EV technology.
Biotech Daily’s Tim Boreham likes Exopharm’s focus: “Given the scientifically complex nature of Exopharm’s quest to develop exosomes into therapeutics, it’s good to see that founder and chief executive Ian Dixon hasn’t lost sight of the commercial basics.” Read the full article here.
MST Access, a division of MST Financial which provides institutional-grade research for small and medium cap companies, has initiated coverage of Exopharm Ltd (ASX: EX1). Read the full report here.
Their Curiosity and Enthusiasm are Infectious… Recently Chief Commercial Officer Chris Baldwin sat down with StockPal to discuss the CEO mindset. Read Chris’ thoughts on Exopharm, measuring success, and the future of exosome medicines. Read the full article on Stockpal Asia.
BD Team Welcomes Partners The Business Development team is excited to be participating in the virtual “Bio Digital Partnering Convention 2020.” With over 30 meetings with potential business partners from around the globe already planned, they are eager to find partners to help us in our mission to bring exosome medicines to the world. Other […]
Exopharm Webinar May 2020 – Our Strategic Response to COVID-19 Exopharm updates the public on its recent progress and activities. Hosted by Jason Watson, Chair of Exopharm, Ian Dixon (CEO), Gregor Lichtfuss (COO) and Chris Baldwin (CCO) discuss how COVID-19 has affected operations and strategies. The application of Exopharm’s engineered exosome program, Fortrexo, is discussed, […]
Exopharm: Preparation, Demonstration and Reward As a biotech stock, order or to maximise the financial returns from our technologies and products there are a number of aspects to the business of Exopharm. As a headline, we see ourselves as world leaders in a new type of regenerative medicine – harnessing exosomes as the ‘secret sauce’ […]